The Doctor Will See Your Portfolio Now

With sticky adoption, rising cash flow, and a 35% gain this year, this company is proving its place in healthcare’s digital toolkit. The challenge is deciding if you want to pay today’s price for tomorrow’s upside.

When Michael Saylor bought Bitcoin, Wall Street called him reckless.

That move turned into one of the most profitable trades in corporate history. His stock jumped more than 10,000%. His balance sheet became a digital-asset vault.

But here’s the flaw in that model: Bitcoin is static. It doesn’t earn rewards.

This time, the playbook is running with an asset that is more powerful.

BNB fuels the world’s largest exchange. It cuts trading costs, anchors DeFi, powers stablecoin flows, and grows scarcer with every burn. And unlike Bitcoin, it can be staked to generate yield.

That means a treasury full of BNB isn’t just waiting for price appreciation. It’s producing cash flow through validator nodes and staking rewards.

One company has already built a $368 million position, making it the largest BNB treasury on earth.

Wall Street hasn’t noticed. But when it does, the premium will come fast

Get the full story here before the crowd catches on.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Wall Street woke up to a government shutdown hangover. Futures slipped as traders game out how long Capitol Hill chaos drags on and what it means for jobs data that might not even show up this week.

Markets usually shrug off shutdowns, but with rates, inflation, and labor already wobbly, investors are on edge. Until Washington flips the lights back on, every tick feels like trading in the dark.

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.

Email’s great. Texts are faster.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Premarket Earnings:

Economic Reports:

Pfizer (NYSE: PFE) shares perked up about 5% after Trump announced the drug giant will cut prices on all Medicaid prescriptions and roll out TrumpRx, a direct-to-consumer site offering discounts of 40% to 85% on popular meds.

Think rheumatoid arthritis drug Xeljanz or migraine fighter Zavzpret. It’s being billed as “most favoured nation” pricing, which sounds like a diplomatic treaty but is really a political headline grab.

We see this as the lesser evil. Instead of tariffs that could nuke the sector, the administration gets a win and Pfizer gets to control the narrative. Other pharma majors will likely follow with similar deals.

But scratch beneath the surface and not much has changed. Pfizer still faces shrinking COVID revenue, looming patent cliffs, and an R&D pipeline that hasn’t wowed investors lately.

My Take For You: Hold if you’re here for the juicy 6%+ yield. This move doesn’t fix the growth story, but it shields against harsher regulation. Traders who bought the pop should be nimble, these headlines fade quickly.

My Verdict: Reliable for income investors, speculative for growth seekers. Pfizer’s dividend is worth clipping, but don’t expect rocket-fuel returns.

AST SpaceMobile (NASDAQ: ASTS) has been trading like a SpaceX rocket strapped to meme-stock fuel. Barclays just hiked its target to $60 from $37, citing confidence in the company’s plan to beam text, calls, and broadband straight to smartphones. It’s a bold vision to skip towers, skip dead zones, and make the whole planet a cell site.

The market clearly loves it. Shares are up more than 125% this year, though they’ve also whipped around with volatility that could make astronauts queasy. The FCC has signed off on 20 satellites, and liquidity looks solid with more cash than debt.

But let’s not forget: last quarter’s revenue missed by nearly 80% and losses nearly doubled expectations. Execution risk isn’t just on the table, it’s the whole meal. That being said, if they get some good things done, the stock will continue to fly.

My Take For You: Traders can ride momentum while it’s hot, but keep stops tight. Long-term buyers should demand proof of service uptake, not just price-target fairy dust.

My Verdict: A moonshot with real promise but extreme risk. Buy tiny, trade fast, and don’t size it like a core holding until satellites deliver revenue, not hype.

Your portfolio might be doing fine.

But why stop at fine when you could aim for game-changing gains?

Our analysts have just released a new special report, highlighting 5 stocks with the potential to double.

These aren’t random picks.

They were hand-selected because they combine:

Past reports have pinpointed stocks before huge runs of +175%, +498%, even +673%.¹

This exclusive report is yours free—but only until midnight tonight.

[Click here now to download your copy instantly]

Why settle for average when extraordinary is on the table?

Doximity (NYSE: DOCS) has quietly become the must-have app for doctors, part LinkedIn, part Zoom, part job board. With revenue up 15% year over year and free cash flow topping $230 million, the company has found a sweet spot in digital healthcare.

Analysts love the stickiness as physicians log in for networking, referrals, and even telehealth, making it hard to rip the platform out of hospital workflows.

Shares are up more than 35% this year, trading near the top of their 52-week range. Return on equity of 24% shows real efficiency, and technicals point to momentum still in play. The risk, of course, is valuation.

At over 60 times earnings, the stock is priced like it will keep compounding at double-digit rates forever. Any slowdown in hospital budgets or a new competitor could knock that multiple down fast.

My Take For You: If you’re already in, hold. Momentum and fundamentals are working in your favor. If you’re new, wait for a pullback before jumping in.

My Verdict: A high-quality growth story in healthcare, but priced for perfection. Accumulate on dips, otherwise, don’t chase in the 70s.

AES just went from boring utility to takeover bait, with BlackRock’s GIP circling a $38B deal. For a stock that’s been left for dead after the green tax credit rollback, this is like your quiet cousin suddenly getting invited to the prom by the most popular kid. Traders are all over it.

But remember, buyouts aren’t real until the ink’s dry. We’ve all seen plenty of talks that turn into never mind.

Nike just reminded everyone it’s still the biggest name in sneakers. Earnings blew past estimates, and analysts bumped targets. The turnaround is looking real, like when your friend finally quits wearing Crocs and shows up in Air Max again.

The brand power’s undeniable, but the valuation’s still chunky. It’s not clearance-rack cheap, even after the run.

Cal-Maine just dropped its best quarter ever. Specialty eggs and prepared foods are flying off shelves, margins are fat, and they’re swimming in cash. And yet… the stock’s cracking lower in premarket. Sometimes the market just doesn’t like breakfast.

This is a classic sell the news setup, with great fundamentals, but traders were already stuffed on omelets.

Five years ago, hardly anyone cared about Michael Saylor. His software firm was fading. Its cash pile was shrinking in value.

Then he shocked Wall Street: he put it all into Bitcoin.

The stock skyrocketed. MicroStrategy became the world’s largest Bitcoin treasury. Today it’s valued near $100 billion.

But here’s what most investors miss: Bitcoin can’t be staked. It doesn’t earn yield. It just sits there.

Now the same playbook is being applied to a different digital asset — one that does generate cash flow.

BNB.

The native token of Binance, the largest crypto exchange with 280 million users. It fuels transactions, reduces fees, anchors DeFi, and supports stablecoin flows larger than Ethereum. Binance systematically burns it, making it scarcer each quarter.

And unlike Bitcoin, BNB pays yield. A treasury this size can run validator nodes, stake tokens, and earn ongoing rewards — millions annually — while still benefiting from appreciation.

One company has already deployed $368 million into BNB, building the largest BNB treasury in the world.

Yet Wall Street still hasn’t priced it in.

This is the kind of setup insiders dream of: limited downside, asymmetric upside, and a productive asset at the center.

Unlock the name and symbol of this digital currency treasury now.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.